New dosing strategy aims to get vancomycin right for kids with MRSA
NCT ID NCT02694458
First seen Jan 08, 2026 · Last updated Jun 22, 2026 · Updated 32 times
Summary
This study tested a new early dosing strategy for vancomycin in 100 children with MRSA infections. The goal was to reach effective drug levels faster while avoiding toxicity. The new approach used early blood monitoring and a computer model to adjust doses, compared to the usual method of checking levels after 24 hours.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METHICILLIN-RESISTANT STAPHYLOCOCCAL INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Necker-Enfants Malades
Paris, Paris, 75015, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vancomycin
What this could lead to
If successful, this approach could help children with MRSA infections reach the right drug levels sooner, improving treatment and reducing side effects.
What could go wrong
This is a small, single-hospital study (100 children) testing a dosing method, not a new drug. Results may not apply to all hospitals or patient groups.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.